First COVID-19 MRNA Vaccine Is Well Tolerated And Produces Antibodies

Table of contents:

First COVID-19 MRNA Vaccine Is Well Tolerated And Produces Antibodies
First COVID-19 MRNA Vaccine Is Well Tolerated And Produces Antibodies

Video: First COVID-19 MRNA Vaccine Is Well Tolerated And Produces Antibodies

Отличия серверных жестких дисков от десктопных
Video: RNA Vaccines (mRNA Vaccine) - Basis of Pfizer and Moderna COVID-19 vaccines, Animation 2023, February
Anonim

First COVID-19 mRNA vaccine is well tolerated and produces antibodies

The study of the first vaccine against COVID-19 shows promising results Whether it can prevent the disease, the trial, which begins on July 27, will show.

First COVID-19 mRNA vaccine is well tolerated and produces antibodies
First COVID-19 mRNA vaccine is well tolerated and produces antibodies

Photo: Moderna / YouTube

The New England Journal of Medicine has published the results of a phase 1 study of an mRNA vaccine against COVID-19, created by American scientists in conjunction with Moderna. According to these data, the vaccine is well tolerated and causes the production of neutralizing antibodies against the coronavirus.

Research into the mRNA-1273 vaccine began in mid-March. Moderna has previously published preliminary data on the first phase of the study, but many experts pointed out that this information cannot be used to tell whether it was successful.

Scientists criticized the publication on the intermediate successes of the first vaccine against COVID-19

Experts believe that the published data do not allow judging even the early criteria for the effectiveness of the vaccine.

Read the article

The study participants were 45 healthy people aged 18 to 55 years. They received two injections of the vaccine 28 days apart. The aim of the study was to determine the safety of the vaccine and to find out how active the immune system response is caused by low, medium and high doses.

After the second injection, all participants developed antibodies, which neutralized the coronavirus in laboratory experiments. Their number corresponded to the maximum concentrations of antibodies in people who had had COVID-19. In addition, the vaccine stimulated the production of T cells, which are responsible for cellular immune responses.

Most of the participants reported side effects of the vaccine, which included weakness, fever, headache, muscle pain, and injection site reactions. Scientists believe that in none of the cases can these side effects be called serious.

A study on whether this vaccine can actually prevent infection with the new coronavirus is scheduled to begin on July 27. 30 thousand people should take part in the test. Half of them will be vaccinated, the other half will receive a placebo injection. Scientists will then observe in which of the groups more people get sick with COVID-19 in real life.

Popular by topic